(Q52873284)

9 May 2018

title

A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group. (English)

1 reference

9 May 2018

author name string

W G Jones

1

1 reference

9 May 2018

M P Sokal

2

1 reference

9 May 2018

M J Ostrowski

3

1 reference

9 May 2018

D W Newling

4

1 reference

9 May 2018

publication date

1 January 1993

1 reference

9 May 2018

published in

Clinical Oncology

1 reference

9 May 2018

volume

5

1 reference

9 May 2018

page(s)

25-29

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

Biology and management of bladder cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

Advanced transitional cell bladder cancer: a treatable disease

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

Cisplatin combination chemotherapy for elderly patients with urothelial tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

Chemotherapy of urothelial tract tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980691-0

7 January 2021

10.1016/S0936-6555(05)80691-0

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

8424911

1 reference

9 May 2018